Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 2/20 | 0.54 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.54 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.54 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SCN1A | P35498 | 1/20 | 0.42 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.42 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL23199820 | 0.98 | SMN1; SMN2 (0.53) | CHRM4CHRM5CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL16845011 | 0.94 | CHRM4 (0.50) | CHRM4CHRM5CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL1023344 | 0.86 | SCN1A (0.53) | CHRM4CHRM5CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL8702574 | 0.85 | CHRM4 (0.47) | CHRM4CHRM5CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL8709003 | 0.85 | CHRM4 (0.47) | CHRM4CHRM5CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL8706766 | 0.85 | CHRM3 (0.47) | CHRM4CHRM5CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL8706770 | 0.85 | CHRM3 (0.47) | CHRM4CHRM5CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL8702578 | 0.85 | CHRM4 (0.47) | CHRM4CHRM5CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL8708999 | 0.85 | CHRM4 (0.47) | CHRM4CHRM5CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL13841482 | 0.85 | CHRM1 (0.53) | CHRM4CHRM5CHRM1CHRM3SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023105303-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER | KASHIV BIOSCIENCES, LLC (US) | 2023-06-15 | — | — | WO | disclosed |
| US-20210253626-A1 | PRODRUGS OF FULVESTRANT | KI PHARMACEUTICALS, LLC | 2021-08-19 | — | — | US | disclosed |
| EP-3801553-A2 | PRODRUGS OF FULVESTRANT | Kashiv Biosciences, LLC (US) | 2021-04-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210253626-A1 | PRODRUGS OF FULVESTRANT | CYP19A1, PGR, CYP21A2 | CHRM4 4336/4885CHRM5 4146/4885CHRM1 4697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.